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Abstract
The nomenclature and classification of vasculitis has been difficult and controversial for many
decades. This is problematic for both research on vasculitis as well as clinical care of patients with
vasculitis. The first (1994) International Chapel Hill Consensus Conference on the Nomenclature
of Systemic Vasculitides (CHCC) proposed names and definitions for the most common forms of
vasculitis. Since then, there have been substantial advances in our understanding of vasculitis and
changes in medical terminology. In addition, CHCC 1994 did not propose a nomenclature for
some relatively common forms of vasculitis, such as vasculitis secondary to other diseases. To
address these issues, a second International Chapel Hill Consensus Conference was held in 2012.
The goals were to change names and definitions as appropriate, and add important categories of
vasculitis not included in CHCC 1994. This overview summarizes the 2012 CHCC and points out
the changes compared to the 1994 CHCC. Notable changes include the introduction of new terms
such as granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and IgA
vasculitis, and the inclusion of categories for variable vessel vasculitis and secondary forms of
vasculitis.
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Introduction
The 1994 International Chapel Hill Consensus Conference on the Nomenclature of Systemic
Vasculitides (CHCC 1994) proposed names and definitions for the most common forms of
vasculitis [1]. This nomenclature was widely adopted. However, in the intervening years,
there have been substantial advances in our understanding of vasculitis and a trend to reduce
the use of eponyms in medical terminology. In addition, CHCC 1994 focused on a limited
number of vasculitides, and thus did not propose a nomenclature for some relatively
common forms of vasculitis, such as vasculitis secondary to other diseases. To address these
issues, a second International Chapel Hill Consensus Conference was held in 2012 (CHCC
Disclosure: The author has declared no competing interest.
NIH Public Access
Author Manuscript
Clin Exp Nephrol. Author manuscript; available in PMC 2014 October 01.
Published in final edited form as:






















2012) [2]. The goals were to change names and definitions as appropriate, and add important
categories of vasculitis not included in CHCC 1994. This overview will summarize the
proposals of the CHCC 2012 [2] (Table 1, Fig 1).
The product of the CHCC is a nomenclature system (nosology) and does not specify criteria
by which patients are classified for clinical studies or diagnosed for clinical care. A
nomenclature system provides names and definitions. Classification and diagnostic criteria
are findings that are used to conclude that a specific category of disease is present in a
specific patient. The definition of a disease provides the framework for developing
classification and diagnostic criteria, but the criteria must be developed and validated by
observations of cohorts of patients.
Large vessel vasculitis (LVV)
CHCC 2012 [2] defines LVV as vasculitis affecting the aorta and its major branches more
often than other vasculitides, however, any size artery may be affected. This definition does
not state that LVV predominantly affects large vessels because in many patients the number
of medium and small arteries affected is greater than the number of large arteries affected.
For example, only a few branches of the carotid arteries may be affected when there is
involvement of numerous small branches extending into the head and neck, for example
small ocular and periocular arteries. The two major variants of LVV are Takayasu arteritis
(TA) and giant cell arteritis (GCA)
TA is arteritis, often granulomatous, predominantly affecting the aorta and its major
branches [2]. Onset usually is in patients younger than 50. GCA is arteritis, often
granulomatous, usually affecting the aorta and its major branches, with a predilection for the
branches of the carotid and vertebral arteries. GCA often involves the temporal artery, and
onset is usually in patients older than 50 and often associated with polymyalgia rheumatica.
Thus, the major discriminator between TA and GCA is the age of the patient. This was
concluded after substantial debate and careful review of available research and clinical data
to try to identify other distinguishing features.
Medium vessel vasculitis (MVV)
MVV is vasculitis predominantly affecting medium arteries defined as the main visceral
arteries and their branches. However, any size artery may be affected [2]. Two major
categories are polyarteritis nodosa (PAN) and Kawasaki disease (KD).
PAN is necrotizing arteritis of medium or small arteries without glomerulonephritis or
vasculitis in arterioles, capillaries, or venules; and not associated with ANCA [2]. The
absence of ANCA is a valuable clinical feature in distinguishing PAN from microscopic
polyangiitis [3]. KD is arteritis associated with the mucocutaneous lymph node syndrome
and predominantly affecting medium and small arteries. Coronary arteries are often
involved. KD usually occurs in infants and young children.
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Small vessel vasculitis (SVV)
SVV is divided into antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis
(AAV) and immune complex SVV [2]. This categorization was not in CHCC 1994 and
reflects a greater level of confidence that ANCA are of pathogenic significance in AAV [4].
AAV is necrotizing vasculitis, with few or no immune deposits, predominantly affecting
small vessels, associated with MPO-ANCA or PR3-ANCA [2]. A prefix should be added to
indicate ANCA reactivity, e.g. PR3-ANCA, MPO-ANCA, ANCA-negative. This is
important because mounting evidence indicates that the ANCA specificity identifies distinct
categories of disease [5,6]. AAV is subdivided into microscopic polyangiitis (MPA),
granulomatosis with polyangiitis (Wegener’s) (GPA), and eosinophilic granulomatosis with
polyangiitis (Churg-Strauss) (EGPA) [2]. The eponyms Wegener’s granulomatosis and
Churg-Strauss syndrome were replaced with the more descriptive terms GPA and EGPA
respectively. The change to GPA was influenced by a decision that had already been made
by several relevant medical societies [7].
MPA is necrotizing vasculitis, with few or no immune deposits, predominantly affecting
small vessels [2]. Necrotizing arteritis involving small and medium arteries may be present.
Necrotizing glomerulonephritis is very common. GPA is necrotizing granulomatous
inflammation usually involving the upper and lower respiratory tract, and necrotizing
vasculitis affecting predominantly small to medium vessels [2]. EGPA is eosinophil-rich and
necrotizing granulomatous inflammation often involving the respiratory tract, and
necrotizing vasculitis predominantly affecting small to medium vessels, and associated with
asthma and eosinophilia [2]. ANCA is more frequent in EGPA when glomerulonephritis is
present [8].
Immune complex SVV is vasculitis with moderate to marked vessel wall deposits of
immunoglobulin and complement components predominantly affecting small vessels [2].
Glomerulonephritis is frequent. The categories of immune complex SVV that were included
in CHCC 2012 are anti-glomerular basement membrane (anti-GBM) disease,
cryoglobulinemic vasculitis (CV), IgA vasculitis (Henoch-Schönlein) (IgAV), and
hypocomplementemic urticarial vasculitis (HUV) (anti-C1q vasculitis). Anti-GBM disease
is vasculitis affecting glomerular capillaries, pulmonary capillaries, or both, with basement
membrane deposition of anti-basement membrane autoantibodies [2]. This was included as
an immune complex vasculitis because the pathogenesis involves in situ formation of
immune complexes between anti-GBM antibodies and GBM antigens with resultant
activation of inflammatory mediators. CV is vasculitis with cryoglobulin immune deposits
affecting small vessels and associated with cryoglobulins in serum [2]. IgAV is vasculitis,
with IgA1-dominant immune deposits, affecting small vessels [2]. Glomerulonephritis
indistinguishable from IgA nephropathy may occur. The eponym Henoch-Schönlein was
dropped because of the compelling evidence that this category of vasculitis is caused by
abnormal IgA1 [9]. Hypocomplementemic urticarial vasculitis (HUV) was the least common
immune complex vasculitis that was included. HUV is vasculitis accompanied by urticaria
and hypocomplementemia affecting small vessels and associated with anti-C1q antibodies
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[2]. Glomerulonephritis, arthritis, obstructive pulmonary disease, and ocular inflammation
are common.
Variable vessel vasculitis (VVV)
VVV is vasculitis with no predominant type of vessel involved that can affect vessels of any
size (small, medium, and large) and type (arteries, veins, and capillaries) [2]. Vasculitides
that are included in this category are Behcet’s disease (BD) and Cogan’s syndrome (CS),
neither of which frequently affects the kidneys.
Single-organ vasculitis (SOV)
SOV is vasculitis in a single organ that has no features that indicate that it is a limited
expression of a systemic vasculitis [2]. The involved organ and vessel type should be
included in the name (e.g. cutaneous small vessel vasculitis, testicular arteritis, central
nervous system vasculitis). Some patients originally diagnosed with SOV will develop
additional disease manifestations that warrant re-defining the case as one of the systemic
vasculitides (e.g. cutaneous arteritis later declaring itself as systemic polyarteritis nodosa,
etc.). It is important for nephrologists to note that renal-limited ANCA-associated
glomerulonephritis is a limited expression of a systemic vasculitis and thus is not considered
a SOV.
Vasculitis associated with systemic disease or probable etiology
Vasculitis that is associated with and may be secondary to a systemic disease. The diagnosis
should have a prefix specifying the associated systemic disease (e.g. rheumatoid vasculitis,
lupus vasculitis, etc.) [2]. Likewise, vasculitis associated with a probable etiology should
have a prefix specifying the association (e.g. hydralazine-associated MPA, hepatitis B virus-
associated vasculitis, hepatitis C virus-associated cryoglobulinemic vasculitis, etc.). These
categories emphasize that a primary cause should always be sought in a patient with
vasculitis.
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Diagram depicting the usual distribution of vessel involvement by large vessel vasculitis,
medium vessel vasculitis, and small vessel vasculitis. All 3 major categories of vasculitis
can affect any size artery, although large vessel vasculitis most often affects large arteries.
Medium vessel vasculitis predominantly affects medium arteries but small arteries may be
affected. Small vessel vasculitis predominantly affects venules and capillaries. Immune
complex small vessel vasculitis rarely affects arteries. Note that ANCA (antineutrophil
cytoplasmic antibody) associated vasculitis affects a broader spectrum of vessels than
immune complex vasculitis. Reproduced from reference 2 with permission.
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Names for vasculitides adopted by the 2012 International Chapel Hill Consensus Conference on the
Nomenclature of Vasculitides. The items highlighted in red are changes or additions compared to the 1994
International Chapel Hill Consensus Conference on the Nomenclature of Vasculitides. Modified from
reference 2.
Large vessel vasculitis (LVV)
 Takayasu arteritis (TAK)
 Giant cell arteritis (GCA)
Medium vessel vasculitis (MVV)
 Polyarteritis nodosa (PAN)
 Kawasaki disease (KD)
Small vessel vasculitis (SVV)
 Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV)
  Microscopic polyangiitis (MPA)
  Granulomatosis with polyangiitis (Wegener’s) (GPA)
  Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA)
 Immune complex SVV
  Anti-glomerular basement membrane (anti-GBM) disease
  Cryoglobulinemic vasculitis (CV)
  IgA vasculitis (Henoch-Schönlein) (IgAV)
  Hypocomplementemic urticarial vasculitis (HUV) (anti-C1q vasculitis)
Variable vessel vasculitis (VVV)
 Behcet’s disease (BD)
 Cogan’s syndrome (CS)
Single-organ vasculitis (SOV)
 Cutaneous leukocytoclastic angiitis
 Cutaneous arteritis
 Primary central nervous system vasculitis Isolated aortitis
 Others





Vasculitis associated with probable etiology
 Hepatitis C virus–associated cryoglobulinemic vasculitis
 Hepatitis B virus–associated vasculitis
 Syphilis-associated aortitis
 Drug-associated immune complex vasculitis
 Drug-associated ANCA-associated vasculitis
 Cancer-associated vasculitis
 Others
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